Dimethaid announces Annual Meeting date
cnw.ca
TORONTO, June 9 /CNW/ - Pharmaceutical developer Dimethaid Research Inc.
(TSX: DMX) announced today that its board of directors has scheduled the
Annual General Meeting of Shareholders for September 21, 2004 to consider
annual business, including the matters raised in the requisition received from
a dissident group of shareholders on May 19, 2004. The Company has set August
3, 2004 as the record date for the meeting. The Annual General Meeting, to be
held in Toronto, Ontario, has been moved up from its originally anticipated
late October date. The company has accelerated auditing procedures to
accommodate this condensed timeline and avoid the unnecessary cost of two
shareholder meetings.
About Dimethaid Research Inc.
Dimethaid Research Inc. is a publicly traded, Canadian, pharmaceutical
company headquartered in Markham, Ontario, with manufacturing facilities in
Varennes, Québec and Wanzleben, Germany. The company develops and
commercializes targeted therapeutic drugs designed to produce minimal side
effects. Dimethaid's two technology platforms focus on immune system
regulation and transcellular drug delivery. Products are aimed at expanding
treatment options in oncology, immunology, rheumatology and the therapeutic
management of chronic viral infections. For more information, please visit
www.dimethaid.com.
This release may contain forward-looking statements, subject to risks and
uncertainties beyond management's control. Actual results could differ
materially from those expressed here. Risk factors are discussed in the
Company's annual information form filed with the securities commissions in
each of the provinces of Canada. The Company undertakes no obligation to
revise forward-looking statements in light of future events.
%SEDAR: 00002418EF |
